LANGHORNE, Pa.--(BUSINESS WIRE)--Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.
“Techdow USA is excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin,” said Darren Alkins, Chief Executive Officer of Techdow USA. “As a vertically integrated company in this complex environment with difficult to source raw material and state-of-the-art prefilled syringe manufacturing, our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing. Techdow USA will be a long-term reliable resource to the marketplace.”
The launch of Enoxaparin will compliment Techdow USA’s existing Heparin Sodium injection business, which was successfully launched in 2022.
Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million, according to IQVIA Health for the 12 months ending December, 2022.
Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs.
To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For more information, please visit www.techdowusa.com.
*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC
